KENILWORTH, N.J.--(BUSINESS WIRE)--ILÚM Health Solutions, a provider of technology and services to support infectious disease management, today announced that data demonstrating the implementation and evaluation of its electronic antimicrobial prior authorization (PA) approval process at the Hospital of the University of Pennsylvania, will be presented at ID Week 2018, to be held October 3-7 in San Francisco.
Prior authorization of antimicrobial agents is recommended by the CDC as a broad antimicrobial stewardship (AMS) intervention and has been a cornerstone of the Hospital of the University of Pennsylvania (HUP) AMS program since its inception. Hospitals utilizing prior authorization require providers to obtain approval from the AMS team prior to prescribing specific restricted antimicrobials. The PA approval process may reduce initiation of inappropriate or unnecessary antimicrobial agents while also serving to educate providers at prime decision-making moments and inform future treatment choices; however, securing AMS team approval can be a cumbersome process that can delay appropriate treatment.
“Effectively managing patients with infectious diseases requires rapidly getting the right information to the right people to optimize decision-making,” said Brandon Palermo, MD, ILÚM chief medical officer. “We look forward to sharing data that demonstrates how ILÚM’s technologies can transform critical use processes, support antibiotic stewardship at the point-of-care, enable efficiencies in terms of time, and most importantly, improve the quality of care provided to patients.”
“Calling the ID approval pager, waiting for a callback, discussing the case with the AMS team, and receiving approval or an alternative recommendation can be a challenging process and for a very ill patient requires time that he or she may not have,” said Jimish M. Mehta, PharmD, ILÚM vice president of product. “For the first time, we have baseline data that provides insight into how a big university system integrated and enthusiastically adopted an electronic PA system. “
Presentations by ILÚM Health Solutions and its collaborators will take place as follows:
Title: Implementation and Evaluation of an Electronic
Antimicrobial Prior Authorization Approval Process at a Large
Academic Medical Center
Date and Time: Thursday, October 4,
2018 12:30-1:45 pm
Location: Room: S Poster Hall
Poster
Presentation: 184
Session: Antimicrobial Stewardship: Interventions
Leveraging the Electronic Health Record
Title: Clinical Impact of Real-Time Predictive Model to
Facilitate Antibiotic Prescribing in Gram-Negative Bacteremia
Date
and Time: Saturday, October 6, 2018 12:30-1:45 pm
Location: Room: S
Poster Hall
Poster Presentation: 1800
Session: Antimicrobial
Stewardship: Impact of New Diagnostics
Title: External Validation of Precision Antibiotic Therapy for
Enterococcal Bloodstream Infections
Date and Time:
Saturday, October 6, 2018: 12:30 PM-1:45 PM
Location: Room: S
Poster Hall
Poster Presentation: 1814
Session: Antimicrobial
Stewardship: New Methods and Metrics
About ILÚM
ILÚM Health Solutions is a provider of technology and services to support infectious disease management. ILÚM is part of Healthcare Services & Solutions, LLC, a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), an independent business unit focused on improving the value of care delivered to patients through evidence-based services and solutions. For more information, visit www.ILÚMhealthsolutions.com and connect with us on Twitter and LinkedIn.
